These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18474502)

  • 1. Antifungal therapies in the intensive care unit.
    Chowdhry R; Marshall WL
    J Intensive Care Med; 2008; 23(3):151-8. PubMed ID: 18474502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies.
    Bassetti M; Righi E; Tumbarello M; Di Biagio A; Rosso R; Viscoli C
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):875-85. PubMed ID: 17140362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fungal infections and their treatment in the intensive care unit.
    Sarosi GA
    Curr Opin Crit Care; 2006 Oct; 12(5):464-9. PubMed ID: 16943727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.
    Playford EG; Marriott D; Nguyen Q; Chen S; Ellis D; Slavin M; Sorrell TC
    Crit Care Med; 2008 Jul; 36(7):2034-9. PubMed ID: 18552700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations.
    Lipsett PA
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S193-9. PubMed ID: 15546117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical critical care: fungal infections in surgical patients.
    Lipsett PA
    Crit Care Med; 2006 Sep; 34(9 Suppl):S215-24. PubMed ID: 16917426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs.
    Swoboda S; Lichtenstern C; Ober MC; Taylor LA; Störzinger D; Michel A; Brobeil A; Mieth M; Hofer S; Sonntag HG; Hoppe-Tichy T; Weigand MA
    Chemotherapy; 2009; 55(6):418-24. PubMed ID: 19996586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging fungal resistance.
    Baddley JW; Moser SA
    Clin Lab Med; 2004 Sep; 24(3):721-35, vii. PubMed ID: 15325062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fungal prophylaxis in very low birth weight neonates: nystatin, fluconazole or nothing?
    Isaacs D
    Curr Opin Infect Dis; 2008 Jun; 21(3):246-50. PubMed ID: 18448968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New antifungal agents in pediatric practice.
    Das S; Shivaprakash MR; Chakrabarti A
    Indian Pediatr; 2009 Mar; 46(3):225-31. PubMed ID: 19346570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic antifungal therapy in the intensive care unit.
    Rex JH; Sobel JD
    Clin Infect Dis; 2001 Apr; 32(8):1191-200. PubMed ID: 11283809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antimicrobial agents for use in the intensive care unit.
    Ritchie DJ; Alexander BT; Finnegan PM
    Infect Dis Clin North Am; 2009 Sep; 23(3):665-81. PubMed ID: 19665089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
    ; Böhme A; Ruhnke M; Buchheidt D; Cornely OA; Einsele H; Enzensberger R; Hebart H; Heinz W; Junghanss C; Karthaus M; Krüger W; Krug U; Kubin T; Penack O; Reichert D; Reuter S; Silling G; Südhoff T; Ullmann AJ; Maschmeyer G
    Ann Hematol; 2009 Feb; 88(2):97-110. PubMed ID: 18853161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients?
    Salavert M
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S149-53. PubMed ID: 19013340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections.
    Cornely OA
    Infection; 2008 Aug; 36(4):296-313. PubMed ID: 18642109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Iatrogenic mycoses with deep visceral localization caused by opportunistic fungi].
    Drouhet E; Dupont B
    Dermatologica; 1979; 159(Suppl 1):94-112. PubMed ID: 573715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fungal infections in the intensive care unit].
    Kerwat K; Rolfes C; Wulf H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2011 Nov; 46(11-12):744-5. PubMed ID: 22161906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.